Japanese Pharma companies have traditionally not participated in the support of product development for the emerging world. They've typically chosen to allocate R&D funds to their own market and faster growing Western economies. Apparently this is about to change.
Five Big Pharma's in Japan, along with the Bill & Melinda Gates Foundation, are pledging to spend $100 M over the next 5 years to make a dent versus HIV, malaria, TB and other tropical diseases. The Japanese government will kick in as well. The spending will come in the form of research grants and will also provide access to company chemical libraries. See Fierce Biotech.
Better late than never.
Posted by Bruce Lehr May 28th 2013.